A pioneering cell therapy designed to treat patients with congestive heart failure did not meet its primary endpoint in a Phase 3 European trial. But the developer, Celyad SA, said a subgroup did show statistical significance. ---Subscribe to MedNous to access this article--- Company News Clinical Research
